Skip to content

Study of the Nutraceutical Properties and Health Benefits of Traditional Components of the Mediterranean Diet

Study of the Nutraceutical Properties and Health Benefits of Traditional Components of the Mediterranean Diet - A Cross Over Interventional Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01890070
Enrollment
50
Registered
2013-07-01
Start date
2013-05-31
Completion date
Unknown
Last updated
2015-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

mediterranean diet, nutrigenomics, body composition, inflammation, oxidative stress

Brief summary

The present protocol is designed to conduct nutrigenomic and nutrigenetic studies on foods conforming to the Mediterranean diet, in order to determine the effect functional foods have on blood parameters (cholesterol metabolism, glucose metabolism, hepatic function, inflammation, nutritional status) and body composition in the context of four different diets (standard, high fat, high protein, low carbohydrate). The study focuses on the effect of these nutraceutical foods in relation to different diets. Diets were chosen to reflect the standard reference diets used by the general population, so as the outcomes of the addition of each interventional food element may be interpreted in the context of a variety of dietary patterns.

Detailed description

This study envisages the enrollment of subjects, to be recruited consecutively from May 2013 to May 2015 from the staff of the laboratory of the Evaluation of Nutritional State, Nutrigenetics and nutrigenomics of the Human Nutrition and Diet section of the University of Rome Tor Vergata. The study will be conducted in accordance with the Declaration of Helsinki, and approved by the Committee of the Ministero delle Politiche Alimentari e Forestali (MIPAAF) , Italy, approved by DM 06/12/2011 n° prot. 32064. All participants will be required to provide written informed consent for the study. At the time of recruitment, relevant subject data will be collected including clinical history, dietary habits, pharmacological therapy, smoking habit, alcohol consumption and level of physical activity. Exclusion criteria include history of coronary vascular disease, peripheral or cerebro- vascular disease, hepatic disease, diagnosis of diabetes mellitus, autoimmune disease, immunodeficiency syndrome or malignant neoplasia. The subjects enrolled will undergo: * Anthropometric measures (body weight, height, waist, hip, abdominal, neck, arm and forearm circumferences). * Skin fold measurements (bicipital, tricipital, subscapular, pectoral, supra iliac, abdominal, anterior thigh, internal thigh, supra patellar and popliteal); * Blood Pressure; * Body composition evaluation (bone, fat and lean mass), evaluated by DEXA (iDXA; GE * Medical Systems, Milwaukee, WI) (Dual energy X-ray Absorptiometry; DPX Lunar Radiation Corp., Madison, Wisconsin, USA); * Distribution of body fluids, evaluated by bioimpedensometry. Resistance, reactance, phase angle at 50 kHz will be measured using the Bioelectrical Impedance Analysis method (BIA 101S, by Akern/RIL System-Florence * Analysis of genetic expression Participants will be randomized into groups. Each group will cycle through different interventions, according to a cross over study. The interventions are represented by different dietary plans based on different meals, consisting of: 1. Standard Diet (SD) alone, and SD with functional food (40g of hazelnuts or 150 ml of biological red wine, or 100g of chestnuts, or 200g of wild mixed greens, or 100 g of olive oil, or 100 g of chocolate); 2. High Fat diet (HF) alone, and HF with functional food (40g of hazelnuts or 150 ml of biological red wine, or 100g of chestnuts, or 200g of wild mixed greens, or 100 g of olive oil, or 100 g of chocolate). 3. Low Carbohydrate diet (LC) alone, and LC with functional food (40g of hazelnuts or 150 ml of biological red wine, or 100g of chestnuts, or 200g of wild mixed greens, or 100 g of olive oil, or 100 g of chocolate). 4. High Protein (HP) alone, and HP with functional food (40g of hazelnuts or 150 ml of biological red wine, or 100g of chestnuts, or 200g of wild mixed greens, or 100 g of olive oil, or 100 g of chocolate). The duration of the experimental period is 4 weeks for each diet, with a wash-out period of 3 weeks at the beginning of the study between one diet and the next.

Interventions

DIETARY_SUPPLEMENTHazelnuts

Italian hazelnuts from Piedmont with Protected Geographical Indication Certification

DIETARY_SUPPLEMENTChocolate

Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)

DIETARY_SUPPLEMENTRed wine

Italian Organic Red Wine

DIETARY_SUPPLEMENTOlive Oil

Italian Organic Olive Oil

DIETARY_SUPPLEMENTWild mixed greens

Italian organic wild mixed greens

DIETARY_SUPPLEMENTChestnut

Italian Organic Chestnut

Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)

Sponsors

University of Rome Tor Vergata
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Age: 18 to 75 years inclusive BMI \>19 kg/m2 \-

Exclusion criteria

* Past history of ischaemic coronary artery disease * Peripheral or cerebral vasculopathy * Hepatic disease * Diabetes Mellitus * Autoimmune disease * HIV/AIDS * Neoplastic disease * Use of the following medications: lipid-lowering medications, oral anti-diabetic medication or insulin, nitroglycerin, corticosteroids.

Design outcomes

Primary

MeasureTime frameDescription
Sarcopenic indexVariation in sarcopenic index from baseline to 4 weeksTo calculate the sarcopenic index three calculations will be made: Body Cell Mass Index from bioelectrical impedance analysis (body cell mass in kilograms divided by height in metres squared),and the Appendicular Skeletal Muscle Index (sum of appendicular muscle mass divided by height in metres squared)and Relative Skeletal Muscle Index (total body lean mass divided by height in metres squared)both calculated from dual-energy X-ray asorptiometry.

Secondary

MeasureTime frameDescription
Cardiovascular Risk IndexVariation in cardiovascular risk index from baseline to 4 weeksCardiovascular Risk Index will be calculated from 3 formulas: Total Cholesterol (mg/dl) divided by High Density Lipoprotein (mg/dl), Low Density Lipoprotein (mg/dl) divided by High Density Lipoprotein (mg/dl), Log10 Triglycerides (mg/dl) divided by High Density Lipoprotein (mg/dl)
Homeostatic Model Assessment (HOMA-IR)Variation in HOMA from baseline to 4 weeksHOMA will be calculated as follows: Blood glucose (mmol/L) x Blood Insulin (mU/L) divided by 22.5
Prognostic Inflammatory and Nutritional Index (PINI)Variation in PINI from baseline to 4 weeksPINI will be calculated as follows: \[C-reactive Protein (mg/L) multiplied by alpha-1 acid glycoprotein (g/L)\] divided by \[albumin (g/L) multiplied by prealbumin (g/L)\]
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB)Variation in expression of NFkappaB from baseline to 4 weeksMeasurement of gene up-regulation or down-regulation in order of magnitude set at ±2FC (fundamental-costant-based system of units)

Countries

Italy

Contacts

Primary ContactLaura Di Renzo, PhD
laura.di.renzo@uniroma2.it+39 0672596855

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026